ganaxolone and Fragile-X-Syndrome

ganaxolone has been researched along with Fragile-X-Syndrome* in 2 studies

Reviews

1 review(s) available for ganaxolone and Fragile-X-Syndrome

ArticleYear
Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials.
    Neuropharmacology, 2015, Volume: 88

    An increasing number of studies implicate the GABAAergic system in the pathophysiology of the fragile X syndrome, a frequent cause of intellectual disability and autism. Animal models have proven invaluable in unravelling the molecular mechanisms underlying the disorder. Multiple defects in this inhibitory system have been identified in Fmr1 knockout mice, including altered expression of various components, aberrant GABAA receptor-mediated signalling, altered GABA concentrations and anatomical defects in GABAergic neurons. Aberrations compatible with those described in the mouse model were detected in dfmr1 deficient Drosophila melanogaster, a validated fly model for the fragile X syndrome. Treatment with drugs that ameliorate the GABAAergic deficiency in both animal models have demonstrated that the GABAA receptor is a promising target for the treatment of fragile X patients. Based on these preclinical studies, clinical trials in patients have been initiated.

    Topics: Animals; Brain; Clinical Trials as Topic; Disease Models, Animal; Fragile X Syndrome; GABA Modulators; Humans; Pregnanolone; Receptors, GABA-A

2015

Other Studies

1 other study(ies) available for ganaxolone and Fragile-X-Syndrome

ArticleYear
The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.
    Cell cycle (Georgetown, Tex.), 2015, Volume: 14, Issue:18

    Previous research indicates that the GABAAergic system is involved in the pathophysiology of the fragile X syndrome, a frequent form of inherited intellectual disability and associated with autism spectrum disorder. However, the molecular mechanism underlying GABAAergic deficits has remained largely unknown. Here, we demonstrate reduced mRNA expression of GABAA receptor subunits in the cortex and cerebellum of young Fmr1 knockout mice. In addition, we show that the previously reported underexpression of specific subunits of the GABAA receptor can be corrected in YAC transgenic rescue mice, containing the full-length human FMR1 gene in an Fmr1 knockout background. Moreover, we demonstrate that FMRP directly binds several GABAA receptor mRNAs. Finally, positive allosteric modulation of GABAA receptors with the neurosteroid ganaxolone can modulate specific behaviors in Fmr1 knockout mice, emphasizing the therapeutic potential of the receptor.

    Topics: Animals; Fragile X Mental Retardation Protein; Fragile X Syndrome; GABA-A Receptor Antagonists; Genotype; Humans; Male; Mice; Mice, Knockout; Mice, Transgenic; Pregnanolone; Receptors, GABA-A; RNA, Messenger

2015